文献速递血管炎

巨细胞动脉炎患者治疗前及治疗后3天和10天超声敏感性与评分的连续评估

Serial assessment of ultrasound sensitivity and scores in patients with giant cell arteritis before and 3 and 10 days after treatment.
PubMed 文献 · Rheumatology (Oxford) · 2025-01-01

本研究前瞻性纳入48例未治疗的新发巨细胞动脉炎(GCA)患者,在糖皮质激素(GC)治疗前及治疗后3天和10天重复血管超声,并与18F-FDG PET/CT和颞动脉活检对照。治疗前超声评估全部血管的敏感性为94%,第3天和第10天分别降至92%和83%;第10天颞动脉超声敏感性降至53%,而大血管超声敏感性为60%。中位OGUS评分在治疗后3天和10天均下降,中位晕征计数第10天下降。作者认为这些发现与EULAR推荐一致,鼓励尽早(最好3天内)进行超声评估以确保准确诊断。

要点

  • 治疗前超声评估全部血管敏感性94%,第3天92%,第10天83%。
  • 第10天颞动脉超声敏感性降至53%,大血管超声敏感性为60%。
  • 中位OGUS评分从1.06降至第3天0.95和第10天0.90。

核心结论

  • 以OGUS表达的血管炎性超声表现在GC治疗3天后即减弱。
  • 颞动脉超声敏感性在10天后下降,而大血管超声较不易变化,凸显大血管评估的重要性。
  • 这些发现与EULAR推荐一致,鼓励尽早(最好3天内)进行超声评估以确保准确诊断。

研究设计与样本

  • 前瞻性纳入未治疗的新发GCA患者,所有患者均行18F-FDG PET/CT、超声和颞动脉活检。
  • 超声在GC开始后3天和10天重复进行,评估内膜-中膜厚度和晕征,计算OGUS评分和晕征计数(HC)。
  • 超声检查者对临床数据非盲,共纳入48例患者。

主要发现

  • GC暴露前超声评估全部血管、颞动脉和大血管的敏感性分别为94%(95%CI 83-99)、73%(95%CI 58-85)和71%(95%CI 56-83)。
  • 第3天和第10天总体超声敏感性分别为92%(95%CI 78-98,P=0.16)和83%(95%CI 69-92,P=0.10)。
  • 第10天颞动脉超声和大血管超声敏感性分别为53%(95%CI 38-68,P<0.01)和60%(95%CI 44-74,P=0.13)。
  • 中位OGUS从1.06(IQR 0.83-1.24)降至第3天0.95(IQR 0.78-1.14,P<0.01)和第10天0.90(IQR 0.73-1.01,P<0.001)。
  • 中位HC从3(IQR 2-5)降至第10天2(IQR 1-4,P<0.01)。

临床怎么用

  • 作者认为,这些发现与EULAR推荐一致,鼓励尽早(最好3天内)进行超声评估以确保准确诊断。

局限性

  • 超声检查者对临床数据非盲。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The objective of this study was to evaluate the sensitivity and scores of vascular US before and after initiating glucocorticoid (GC) treatment in patients with new-onset giant cell arteritis (GCA). METHODS: Treatment-naïve patients with GCA were prospectively included. 18F-fluorodeoxyglucose (18F-FDG) PET/CT, US and temporal artery (TA) biopsy were performed in all patients. US was repeated 3 and 10 days after GC commencement. Intima-media thickness and presence of halo signs were assessed. Sonographers were unblinded to the clinical data. The OMERACT GCA Ultrasonography score (OGUS) and the halo count (HC) were calculated. RESULTS: Forty-eight patients were included. Before GC exposure, US sensitivity was 94% (95% CI: 83-99), 73% (95% CI: 58-85), and 71% (95% CI: 56-83) when assessing all vessels, TAs, and large vessels (LVs), respectively. At day 3 and 10, the overall US sensitivity was 92% (95% CI: 78-98, P = 0.16) and 83% (95% CI: 69-92, P = 0.10), respectively. At day 10, the TA-US and LV-US sensitivity was 53% (95% CI: 38-68, P < 0.01) and 60% (95% CI: 44-74, P = 0.13), respectively. The median OGUS decreased from 1.06 (IQR 0.83-1.24) to 0.95 (IQR 0.78-1.14, P < 0.01) and 0.90 (IQR 0.73-1.01, P < 0.001) after 3 and 10 days, respectively. The median HC decreased from 3 (IQR 2-5) to 2 (IQR 1-4, P < 0.01) after 10 days. CONCLUSION: The vasculitic US findings expressed by OGUS diminished after 3 days of GC treatment. TA-US sensitivity decreased after 10 days, whereas LV-US was less likely to change, highlighting the importance of LV-assessment. Consistent with the EULAR recommendations, these findings encourage prompt US assessment, preferably within 3 days, to ensure an accurate diagnosis.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Hansen M, Hansen IT, Keller KK, et al. Serial assessment of ultrasound sensitivity and scores in patients with giant cell arteritis before and 3 and 10 days after treatment. Rheumatology (Oxford). 2025. PMID: 39400596. doi:10.1093/rheumatology/keae551

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。